# Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema

> **NCT03759860** · PHASE4 · UNKNOWN · sponsor: **CynosureLutronic** · enrollment: 12 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **COMBINATION_PRODUCT:** R:GEN laser treatment (Selective Retina Therapy) and Lucentis (ranibizumab) combination therapy

## Key facts

- **NCT ID:** NCT03759860
- **Lead sponsor:** CynosureLutronic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-08
- **Primary completion:** 2019-07-30
- **Final completion:** 2020-07-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03759860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03759860, "Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03759860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*